Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Adrien Contejean, Clemence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Pica Gian-Matteo, Dony Arthur, Amine Belhabri, Mauricette Michallet, Pedro Chorao, Mael Heiblig, Gaspar Aspas Requena

Blood (2024) 144 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2024-208577

Published: 2024

Journal Articles

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Mael Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Martin Carre, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Zofia Gross

Blood (2024) 144 (Supplement 1): 846.

https://doi.org/10.1182/blood-2024-207764

Published: 2024

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Adrien Contejean, Pierre Chauvelot, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Clémence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Gian Matteo Pica, Arthur Dony, Amine Belhabri, Mauricette Michallet, Zofia Gross, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2024-207605

Published: 2024

Journal Articles

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carre, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2024-208817

Published: 2024

Journal Articles

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Emmanuelle Tavernier, Jérôme Cornillon, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carré, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2024-203496

Published: 2024

Journal Articles

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Pierre-Yves Dumas, Sarah Bertoli, Clémence Santana, Mael Heiblig, Thibaut Leguay, Suzanne Tavitian, Eric Delabesse, Émilie Klein, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2024-210596

Published: 2024

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Blood (2023) 142 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2023-185945

Published: 2023

Journal Articles

Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study

Thomas Cluzeau, Marie Sebert, Michael Loschi, Lionel Ades, Sylvain Thepot, Martin Carre, Nicolas Duployez, Rosa Sapena, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Marie Robin

Blood (2023) 142 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2023-178021

Published: 2023

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Blood (2023) 142 (Supplement 1): 975.

https://doi.org/10.1182/blood-2023-173518

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Blood (2023) 142 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2023-173656

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carre, Mathieu Meunier, Emmanuelle Tavernier, Jérôme Cornillon, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Boullanger FOW HENG Nadine, Daciana Claudia Antal, Gian Matteo Pica, Dony Arthur, Clémence Santana, Clement Rocher, Mael Heiblig

Blood (2023) 142 (Supplement 1): 590.

https://doi.org/10.1182/blood-2023-187331

Published: 2023

Journal Articles

Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Blood (2022) 140 (Supplement 1): 6149–6151.

https://doi.org/10.1182/blood-2022-158665

Published: 2022

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

NARROW

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only